Calcitonin, an update

Bone

Volumn 24, Issue 5 SUPPL., 1999, Pages 63S-65S

  Martin, T J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CALCITONIN; CALCITONIN RECEPTOR; CORTICOSTEROID;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE PAIN; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; COMPRESSION; HUMAN; HYDROXYPROLINE URINE LEVEL; IN VITRO STUDY; INTRANASAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; RECEPTOR DOWN REGULATION; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYPHYLAXIS;

EID: 0032937628     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00068-X     Document Type: Article

References (16)

1. Binstock M.L., Mundy G.R. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 93:1980;269-272.
2. De Rose J., Singer F.R., Avramides A., et al. Treatment of Paget's disease. Am J Med. 50:1974;858-866.
3. Douglas D.L., Duckworth J., Kanis J.A., Jefferson A.A., Martin T.J., Russell R.G.G. Spinal cord dysfunction in Paget's disease of bone. J Bone Jt Surg. 63-B:1981;495-503.
4. Findlay D.M., Michelangeli V.P., Robinson P.J. Protein kinase-C-induced down regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN cells. Endocrinology. 125:1989;2656-2663.
5. Hosking D.J., Denton L.B., Cadge B., Martin T.J. Functional significance of antibody formation after long-term calcitonin therapy. Clin Endocrinol. 10:1979;243-252.
6. Ikegame M., Rakopoulos M., Zhou H., et al. Calcitonin receptor isoforms in mouse and rat osteoclasts. J Bone Miner Res. 10:1994;59-65.
7. Ikegame M., Rakopoulos M., Martin T.J., et al. Effects of continuous calcitonin treatment on osteoclast-like cell development and calcitonin receptor in mouse bone marrow cultures. J Bone Miner Res. 11:1996;456-465.
8. Martin T.J., Findlay D.M., Moseley J.M., Sexton P.M. Calcitonin. Avioli L.V., Krane S.M. Metabolic Bone Disease and Clinically Related Disorders, 3rd ed. 1998;95-121 Academic, New York.
9. Messer H.H., Copp D.H. Changes in response to calcitonin following prolonged administration to intact rats. Proc Soc Exp Biol Med. 146:1974;643-647.
10. Raisz L.G., Wener J.A., Trummel C.L., et al. Induction, inhibition and escape as phenomena in bone resorption. Excerpta Medica Int Congr Series. 243:1972;446-453.
11. Rakopoulos M., Ikegame M., Findlay D.M., et al. Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone. 17:1995;447-453.
12. Schneider H.-G., Michelangeli V.P., Frampton R.J., et al. Transforming growth factor-β modulates receptor binding of calciotropic hormones and G protein-mediated adenylate cyclase responses in osteoblast-like cells. Endocrinology. 131:1992;1383-1389.
13. Tashjian A.H. Jr, Wright D.R., Ivey J.L., et al. Calcitonin binding sites in bone Relationship to biological response and "escape." Recent Progr Horm Res. 34:1978;285-334.
14. Wada S., Akatsu T., Tamura T., et al. Glucocorticoid regulation of calcitonin receptor in mouse osteoclast-like multinucleated cells. J Bone Miner Res. 9:1994;1705-1712.
15. Wada S., Udagawa N., Akatsu T., Nagata N., Martin T.J., Findlay D.M. Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology. 138:1997;521-529.
16. Wada S., Udagawa N., Nagata N., et al. Calcitonin receptor down-regulation relates to calcitonin resistance in mature mouse osteoclasts. Endocrinology. 137:1996;1042-1048.